MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Differential Rab10 & Rab8A phosphorylation by LRRK2 variants G2019S & I1371V manifests differences in membrane fluidity & pathogenicity.

KH. Singh, IND. Datta (Bengaluru, India)

Meeting: 2023 International Congress

Abstract Number: 1490

Keywords: Leucine-rich repeat kinase 2(LRRK2), Parkinson’s

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: To evaluate the difference in substrate (Rab8A & Rab10) phosphorylation by LRRK2 variants G2019S & I1371V on membrane fluidity & pathogenicity.

Background: LRRK2 is a multidomain protein reported to have several pathogenic point mutations in Parkinson’s Disease; showing ethnicity bias. The difference between the LRRK2 variants is evident through the reports showing differences with respect to disease risk, disease severity, age of onset, disease progression, brain pathology, clinical symptoms such as RBD, & drug response. PD-causing LRRK2 mutations represent a “gain of function” through a direct activation of kinase activity or by prolonging kinase activity for GTPase domain mutations. Differences among kinase & GTPase domain mutations has been reported in its downstream substrate (Rab) phosphorylation pattern. These may have differential effects on membrane trafficking of proteins & sterols, in turn affecting membrane fluidity & pathogenicity.

Method: SH-SY5Y cells were transfected with WT, LRRK2 G2019S & LRRK2 I1371V variants. Fluorescence polarization was used to study membrane anisotropy. Membrane function such as neurite outgrowth was measured using fluorescent microscopy & level of Caveolin1 was checked using Immunophenotyping. Cholesterol content was measured using ELISA. Substrate phosphorylation (phosphorylated Rab8A, Rab10) & auto-phosphorylation (phosphorylated LRRK2) were measured using Immunophenotyping.

Results: I1371V showed decreased auto-phosphorylation at S935 & increased auto-phosphorylation at S1292 residue while, G2019S showed similar auto-phosphorylation at S935 & decreased auto-phosphorylation at S1292, as compared to the WT. Lesser S1292 phosphorylation at LRRK2 corresponds to lesser neurite length; observed here too in G2019S than I1371V. In contrast, I1371V showed higher Rab8A & Rab10 (substrate) phosphorylation than G2019S. This corresponded to the increased membrane fluidity & decreased Lipid raft (Caveolin1) expression in I1371V than G2019S.

Conclusion: Distinct differences in auto & substrate phosphorylation between variants was manifested through the difference in membrane fluidity, lipid raft expression & neurite length. Importance of featuring the heterogeneity among LRRK2 mutant variants at the cellular level is essential for target-based drug discovery & define predictable population for drug trials targeting LRRK2 protein.

To cite this abstract in AMA style:

KH. Singh, IND. Datta. Differential Rab10 & Rab8A phosphorylation by LRRK2 variants G2019S & I1371V manifests differences in membrane fluidity & pathogenicity. [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/differential-rab10-rab8a-phosphorylation-by-lrrk2-variants-g2019s-i1371v-manifests-differences-in-membrane-fluidity-pathogenicity/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/differential-rab10-rab8a-phosphorylation-by-lrrk2-variants-g2019s-i1371v-manifests-differences-in-membrane-fluidity-pathogenicity/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley